<DOC>
	<DOCNO>NCT02578550</DOCNO>
	<brief_summary>The purpose study evaluate single-dose pharmacokinetics pivotal bioequivalence Darunavir ( DRV ) 800 milligram ( mg ) , Emtricitabine ( FTC ) 200 mg , tenofovir alafenamide ( TAF ) 10 mg administer fixed-dose combination ( FDC ) ( D/C/F/TAF ) relative separate agent ( DRV 800 mg tablet formulation FTC/TAF 200/10 mg FDC ) presence 150 mg Cobicistat ( COBI ) , fed condition , healthy participant .</brief_summary>
	<brief_title>A Bioequivalence Study Darunavir , Emtricitabine , Tenofovir Alafenamide , Presence Cobicistat Healthy Participants</brief_title>
	<detailed_description>This Phase 1 , open-label , randomize , 2-way crossover study 96 healthy adult participant . The study consist 2 treatment session . Participants receive one session single dose darunavir/cobicistat/emtricitabine/tenofovir alafenamide ( D/C/F/TAF ) 800/150/200/10 milligram ( mg ) tablets fixed-dose combination ( FDC ) another session Darunavir ( DRV ) 1x 800 mg tablet , Emtricitabine/ tenofovir alafenamide ( FTC/TAF ) 1x 200/10 mg FDC tablet , Cobicistat ( COBI ) 150 mg 1x 150 mg tablet fed condition . Treatment session separate washout period least 7 day . The duration study individual participant least 12 day , Screening Follow-up include . Participants safety monitor throughout study .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Participant must nonsmoker least 3 month prior selection Participant must healthy basis physical examination , medical history , vital sign , 12lead electrocardiogram ( ECG ) perform Screening . If result outside normal reference range , participant may include list exclusion criterion Investigator judge abnormality deviation normal clinically significant . This determination must record participant 's source document initialed/signed Investigator Participant must body mass index ( BMI ) , 18.5 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) Participant must healthy basis clinical laboratory test perform Screening . If result biochemistry panel , blood coagulation , hematology , urinalysis outside normal reference range , participant may include abnormality deviation normal list exclusion criterion , Investigator judge clinically significant . This determination must record participant 's source document initialed/signed Investigator All female participant , except postmenopausal , must negative serum ( beta‐human chorionic gonadotropin [ beta‐hCG ] ) pregnancy test Screening must breastfeed Screening onwards Participant positive human immunodeficiency virus type ( HIV1 ) human immunodeficiency virus type 2 ( HIV2 ) test Screening Participant hepatitis A , B , C infection ( confirm positive hepatitis A antibody immunoglobulin M ( IgM ) , hepatitis B surface antigen , and/or hepatitis C virus antibody , respectively ) Screening Participant currently significant active gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , endocrinologic , genitourinary , renal , hepatic , respiratory , inflammatory , neoplastic , infectious disease . Currently active dermatological disease would interfere correct assessment possible skin reaction study drug Participant currently significant active diarrhea , nausea , constipation Investigator 's opinion could influence drug absorption bioavailability Participant history renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunodeficiency Virus Type 1 , Human</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Cobicistat</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Tenofovir alafenamide</keyword>
	<keyword>Healthy participant</keyword>
</DOC>